Danish drugmaker Novo Nordisk (NOV: N) is emerging alongside Eli Lilly (NYSE: LLY) as an early frontrunner in the market for obesity treatments.
The company has secured this leadership thanks to its GLP-1 agonist Wegovy (semaglutide), and it is hopeful that its pipeline will maintain this position - an effort aided by its acquisition of Inversago Pharma for up to $1.075 billion in cash if certain development and commercial milestones are achieved.
Inversago Pharma is a private, Montreal, Canada-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze